139183-89-4

Basic information

• Product Name: Methyl iMidazo[1,5-a]pyridine-6-carboxylate
• Synonyms: Methyl iMidazo[1,5-a]pyridine-6-carboxylate;methyl H-imidazo[1,5-a]pyridine-6-carboxylate
• CAS NO: 139183-89-4
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17202
• Mol File: 139183-89-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl iMidazo[1,5-a]pyridine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl iMidazo[1,5-a]pyridine-6-carboxylate(139183-89-4)
• EPA Substance Registry System: Methyl iMidazo[1,5-a]pyridine-6-carboxylate(139183-89-4)

Safety Data

• Hazardous Substances Data: 139183-89-4(Hazardous Substances Data)

Usage

General Description

Methyl imidazo[1,5-a]pyridine-6-carboxylate is a chemical compound with the molecular formula C8H7N3O2. It is a white to off-white solid that is used in the synthesis of pharmaceuticals and organic compounds. This chemical is commonly used as a building block in the development of drugs and novel molecules due to its unique structure and reactivity. It is also known for its ability to act as a pharmacophore, making it a valuable tool in medicinal chemistry research. Methyl imidazo[1,5-a]pyridine-6-carboxylate has potential applications in the treatment of various diseases and medical conditions due to its diverse pharmacological properties.

Upstream product

• 139183-88-3 methyl 6-formylaminomethylnicotinate 
• 139183-87-2 methyl 6-(aminomethyl)nicotinate 
• 22794-96-3 methyl 6-hydroxyiminomethylnicotinate 

Downstream Products

• 1354904-63-4 methyl 3-{[3-(methoxycarbonyl)-4-[(propylcarbamoyl)amino]phenyl]carbonyl}imidazo[1,5-a]pyridine-6-carboxylate 
• 1354904-60-1 3-[(4-amino-3-carboxyphenyl)carbonyl]imidazo[1,5-a]pyridine-6-carboxylic acid 
• 256935-76-9 imidazo[1,5-a]pyridine-6-carboxylic acid 
• 1362159-55-4 N-{[4-(benzenesulfonyl)phenyl]methyl}imidazo[1,5-a]pyridine-6-carboxamide 

Relevant articles and documents

Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

The invention provides compounds of Formula I: 1These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which α7 is known to be involved.

Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives

We prepared a novel series of conformationally restricted fused imidazole derivatives 4b, 4c and 4d (possessing 4,5,6,7-tetrahydroimidazo[4,5- c]pyridine and substituted 4,5,6,7-tetrahydro-1H-benzimidazole for 4b, 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine for 4c and 5,6,7,8- tetrahydroimidazo[1,5-a]pyridine for 4d as a basic amine part and (2- methoxyphenyl)aminocarbonyl group as an aromatic-carbonyl part). Their activities were then evaluated as an 5-hydroxytryptamine (5-HT3) receptor antagonist which may be useful for the treatment of irritable bowel syndrome (IBS) as well as for nausea and vomiting associated with cancer chemotherapy. The most potent compound was N-(2-methoxyphenyl)-4,5,6,7-tetrahydro-1H- benzimidazole-5-carboxamide 14 in this series with an ID50 value of 0.32 μg/kg on the von Bezold-Jarisch reflex in rats and an IC50 value of 0.43 μM on the isolated colonic contraction in guinea pig, approximately ten and two times more potent than ondansetron 1, respectively. The structure- activity relationships (SAR) study suggested that the high potency of 14 may be attributed to the suitable position and direction of the N-C-N centroid in the conformationally restricted imidazole ring against the planar (2-methoxy- phenyl)aminocarbonyl part in the binding of 14 to the receptor.